Premium
Pirfenidone: A Potential New Therapy for Restrictive Allograft Syndrome?
Author(s) -
Vos R.,
Verleden S. E.,
Ruttens D.,
Vandermeulen E.,
Yserbyt J.,
Dupont L. J.,
Van Raemdonck D. E.,
De Raedt N.,
Gheysens O.,
De Jong P. A.,
Verleden G. M.,
Vanaudenaerde B. M.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12474
Subject(s) - medicine , pirfenidone , lung transplantation , lung function , lung , intensive care medicine , idiopathic pulmonary fibrosis
This case report describes the evolution of pulmonary function findings (FVC, FEV 1 and TLC) and CT features with pirfenidone treatment for restrictive allograft syndrome following lung transplantation. Furthermore, we herein report hypermetabolic activity on 18 F‐FDG PET imaging in this setting, which could indicate active fibroproliferation and pleuroparenchymal remodeling. These findings may warrant further investigation.